Gemcitabine chemotherapy induces phenotypic alterations of tumor cells that facilitate antitumor T cell responses in a mouse model of oral cancer

Oral Oncology

Volumn 50, Issue 5, 2014, Pages 457-467

  Tomihara, Kei ^a   Fuse, Hiroki ^a   Heshiki, Wataru ^a   Takei, Rie ^a   Zhang, Bin ^b   Arai, Naoya ^c   Nakamori, Kenji ^a   Noguchi, Makoto ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b NORTHWESTERN UNIVERSITY   (United States)

^c MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antitumor immune response; Chemotherapy; Gemcitabine; Oral cancer

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GEMCITABINE; INTERCELLULAR ADHESION MOLECULE 1; LIPOCORTIN 5; PADGEM PROTEIN; SODIUM CHLORIDE; VASCULAR CELL ADHESION MOLECULE 1; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL DEATH; CELL HOMING; CELL MATURATION; CELL POPULATION; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DENDRITIC CELL; DRUG CYTOTOXICITY; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; MIXED LYMPHOCYTE REACTION; MOUSE; MOUTH CANCER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPPRESSOR CELL; T LYMPHOCYTE; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; C3H MOUSE; DISEASE MODEL; IMMUNOLOGY; MIXED LYMPHOCYTE CULTURE; MOUTH NEOPLASMS; PATHOLOGY;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED C3H; MOUTH NEOPLASMS; PHENOTYPE; T-LYMPHOCYTES;

EID: 84899122784     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2014.01.013     Document Type: Article

References (43)

1. L. Zhang, J.R. Conejo-Garcia, D. Katsaros, P.A. Gimotty, M. Massobrio, and G. Regnani et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer N Engl J Med 348 3 2003 203 213
2. M.J. Turk, J.A. Guevara-Patiño, G.A. Rizzuto, M.E. Engelhorn, S. Sakaguchi, and A.N. Houghton Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells J Exp Med 200 6 2004 771 782
3. J. Galon, A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B. Mlecnik, and C. Lagorce-Pagès et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 313 5795 2006 1960 1964
4. W. Zou Immunosuppressive networks in the tumour environment and their therapeutic relevance Nat Rev Cancer 5 4 2005 263 274
5. L. Zitvogel, L. Apetoh, F. Ghiringhelli, and G. Kroemer Immunological aspects of cancer chemotherapy Nat Rev Immunol 8 1 2008 59 73
6. L. Zitvogel, L. Apetoh, F. Ghiringhelli, F. André, A. Tesniere, and G. Kroemer The anticancer immune response: indispensable for therapeutic success? J Clin Invest 118 6 2008 1991 2001
7. R.G. van der Most, A. Currie, B.W. Robinson, and R.A. Lake Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity Cancer Res 66 2 2006 601 604
8. R. Ramakrishnan, S. Antonia, and D.I. Gabrilovich Combined modality immunotherapy and chemotherapy: a new perspective Cancer Immunol Immunother 57 10 2008 1523 1529
9. J. Umanzor, M. Aguiluz, C. Pineda, S. Andrade, M. Erazo, and C. Flores et al. Concurrent cisplatin/gemcitabine chemotherapy along with radiotherapy in locally advanced cervical carcinoma: a phase II trial Gynecol Oncol 100 1 2006 70 75
10. A. Hilbig, and H. Oettle Gemcitabine in the treatment of metastatic pancreatic cancer Expert Rev Anticancer Ther 8 4 2008 511 523
11. P.A. Philip, J. Benedetti, C.L. Corless, R. Wong, E.M. O'Reilly, and P.J. Flynn et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205 J Clin Oncol 28 22 2010 3605 3610
12. M.D. Shelley, A. Cleves, T.J. Wilt, and M.D. Mason Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma BJU Int 108 2 2011 168 179
13. A.K. Nowak, B.W. Robinson, and R.A. Lake Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy Cancer Res 62 8 2002 2353 2358
14. A.K. Nowak, B.W. Robinson, and R.A. Lake Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors Cancer Res 63 15 2003 4490 4496
15. E. Suzuki, V. Kapoor, A.S. Jassar, L.R. Kaiser, and S.M. Albelda Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity Clin Cancer Res 11 18 2005 6713 6721
16. H.J. Ko, Y.J. Kim, Y.S. Kim, W.S. Chang, S.Y. Ko, and S.Y. Chang et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model Cancer Res 67 15 2007 7477 7486
17. A.K. Nowak, R.A. Lake, A.L. Marzo, B. Scott, W.R. Heath, and E.J. Collins et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells J Immunol 170 10 2003 4905 4913
18. M.L. Levitt, B. Kassem, W.E. Gooding, L.M. Miketic, R.J. Landreneau, and P.F. Ferson et al. Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms Lung Cancer 43 3 2004 335 344
19. J.M. Plate, A.E. Plate, S. Shott, S. Bograd, and J.E. Harris Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas Cancer Immunol Immunother 54 9 2005 915 925
20. P. Correale, M.G. Cusi, K.Y. Tsang, M.T. Del Vecchio, S. Marsili, and M.L. Placa et al. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients J Clin Oncol 23 35 2005 8950 8958
21. L.A. Emens, and E.M. Jaffee Leveraging the activity of tumor vaccines with cytotoxic chemotherapy Cancer Res 65 18 2005 8059 8064
22. L.A. Emens Chemoimmunotherapy Cancer J 16 4 2010 295 303
23. J.P. Machiels, R.T. Reilly, L.A. Emens, A.M. Ercolini, R.Y. Lei, and D. Weintraub et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice Cancer Res 61 9 2001 3689 3697
24. R.E. Merritt, A. Mahtabifard, R.E. Yamada, R.G. Crystal, and R.J. Korst Cisplatin augments cytotoxic T-lymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer J Thorac Cardiovasc Surg 126 5 2003 1609 1617
25. D.I. Gabrilovich, and S. Nagaraj Myeloid-derived suppressor cells as regulators of the immune system Nat Rev Immunol 9 3 2009 162 174
26. P. Sinha, V.K. Clements, S.K. Bunt, S.M. Albelda, and S. Ostrand-Rosenberg Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response J Immunol 179 2 2007 977 983
27. C. Murdoch, M. Muthana, S.B. Coffelt, and C.E. Lewis The role of myeloid cells in the promotion of tumour angiogenesis Nat Rev Cancer 8 8 2008 618 631
28. J.I. Youn, S. Nagaraj, M. Collazo, and D.I. Gabrilovich Subsets of myeloid-derived suppressor cells in tumor-bearing mice J Immunol 181 8 2008 5791 5802
29. J. Vincent, G. Mignot, F. Chalmin, S. Ladoire, M. Bruchard, and A. Chevriaux et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity Cancer Res 70 8 2010 3052 3061
30. W. Zou Regulatory T cells, tumour immunity and immunotherapy Nat Rev Immunol 6 4 2006 295 307
31. A. Bonertz, J. Weitz, D.H. Pietsch, N.N. Rahbari, C. Schlude, and Y. Ge et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma J Clin Invest 119 11 2009 3311 3321
32. L. Strauss, C. Bergmann, W. Gooding, J.T. Johnson, and T.L. Whiteside The frequency and suppressor function of CD4+ CD25 high Foxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck Clin Cancer Res 13 21 2007 6301 6311
33. A.M. Miller, K. Lundberg, V. Ozenci, A.H. Banham, M. Hellström, and L. Egevad et al. CD4+ CD25 high T cells are enriched in the tumor and peripheral blood of prostate cancer patients J Immunol 177 10 2006 7398 7405
34. F. Ghiringhelli, N. Larmonier, E. Schmitt, A. Parcellier, D. Cathelin, and C. Garrido et al. CD4+ CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative Eur J Immunol 34 2 2004 336 344
35. M.E. Lutsiak, R.T. Semnani, R. De Pascalis, S.V. Kashmiri, J. Schlom, and H. Sabzevari Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide Blood 105 7 2005 2862 2868
36. K. Takizawa, R. Kamijo, D. Ito, M. Hatori, K. Sumitani, and M. Nagumo Synergistic induction of ICAM-1 expression by cisplatin and 5-fluorouracil in a cancer cell line via a NF-kappaB independent pathway Br J Cancer 80 7 1999 954 963
37. S. Gasser, S. Orsulic, E.J. Brown, and D.H. Raulet The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor Nature 436 7054 2005 1186 1190
38. S. Armeanu, M. Bitzer, U.M. Lauer, S. Venturelli, A. Pathil, and M. Krusch et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate Cancer Res 65 14 2005 6321 6329
39. E.A. Reits, J.W. Hodge, C.A. Herberts, T.A. Groothuis, M. Chakraborty, and E.K. Wansley et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy J Exp Med 203 5 2006 1259 1271
40. A. Ashkenazi, and V.M. Dixit Death receptors: signaling and modulation Science 281 5381 1998 1305 1308
41. O. Micheau, E. Solary, A. Hammann, F. Martin, and M.T. Dimanche-Boitrel Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity J Natl Cancer Inst 89 11 1997 783 789
42. C.M. van Geelen, E.G. de Vries, T.K. Le, R.P. van Weeghel, and S. de Jong Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines Br J Cancer 89 2 2003 363 373
43. S. Heikaus, K.S. Matuszek, C.V. Suschek, U. Ramp, P. Reinecke, and E. Grinstein et al. Paclitaxel (Taxol)-induced apoptosis in human epithelioid sarcoma cell lines is enhanced by upregulation of CD95 ligand (FasL/Apo-1L) J Cancer Res Clin Oncol 134 6 2008 689 695